Potential New Target Identified in Pancreatic Cancer

Article

Researchers have identified a potential new method for treating pancreatic cancer, using calcium to overload pancreatic cancer cells and, thus, induce cell death in cancerous cells while sparing healthy cells.

Researchers have identified a potential new method for treating pancreatic cancer, using calcium to overload pancreatic cancer cells and, thus, induce cell death in cancerous cells while sparing healthy cells.

The key to this discovery, made by Jason Bruce, PhD, from the Physiological Systems and Disease Research Group at the University of Manchester, and colleagues, was identifying the “power source” for calcium pumps in the cancer cells that keep calcium levels low, assisting in cell survival.

According to background information in the study, maintaining a low concentration of calcium is key to cell survival. Plasma membrane Ca2+ ATPase (PMCA) is a protein in the plasma membrane of cells that removes calcium from the cell. PMCA is fueled using adenosine triphosphate (ATP).

Prior research has shown that many cancer cells, including pancreatic cancer, shift from ATP produced from mitochondria metabolism to a glycolysis ATP. Mitochondria generate approximately 90% of a cells’ energy in normal healthy cells. However, in pancreatic cancer cells it is thought that PMCA may have its own supply of glycolytic ATP, and it is this fuel supply that gives cancer cells a survival advantage over normal cells.

“Designing drugs to cut off this supply to the calcium pumps might be an effective strategy for selectively killing cancer cells while sparing normal cells within the pancreas,” said Bruce in a prepared statement.

In order to determine whether pancreatic cells were fuelled by mitochondrial or glycolytic ATP, the researchers used pancreatic tumor cells to test the effect of mitochondrial and glycolytic inhibition on cell death. The results of the study were published in the Journal of Biological Chemistry.

Mitochondrial inhibition had no effect on cell death compared with control experiments. However, the researchers found that glycolysis inhibition induced ATP depletion, an irreversible increase in calcium, and ultimately cell death.

“Collectively, the present study suggests that glycolytic ATP synthesis is critically important for maintaining PMCA activity and low resting Ca2+, in human pancreatic ductal adenocarcinoma cell lines,” the researchers wrote. “Furthermore, these findings are translational and provide insights into a potentially new therapeutic avenue for the treatment of pancreatic ductal adenocarcinoma.”

Related Videos
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content